Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04561427
Other study ID # COSACM_2020
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2019
Est. completion date February 1, 2022

Study information

Verified date August 2020
Source Hospices Civils de Lyon
Contact Patricia Franco
Phone 4.27.85.60.52
Email patricia.franco@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Narcolepsy is a rare disease that affects 0.05% of the general population. It is characterized by a dysregulation of the sleep wake regulation that leads to uncontrolled sleep episode during day and a disorganized sleep during night. These symptoms are due to a loss of hypocretin neurons in the brain leading to an inability to maintain wake properly. The physiopathology of this rare disease still needs investigations. Since we are a reference center for this disease, we propose to use patients files to better describe and document the sleep characteristics of these children, the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date February 1, 2022
Est. primary completion date February 1, 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria:

- Patients between 0 and 18 years old

- Patients diagnosed with primary or secondary narcolepsy

- From both gender

Exclusion Criteria:

- Patients diagnosed with another sleep disorder

- Healthy patients

- Patients older than 18 years old

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Study of Sleep architecture in children with narcolepsy
Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children

Locations

Country Name City State
France : Sleep pediatric unit , Woman Mother Child Hospital, Hospices Civils de Lyon Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sleep period (SP) evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Total sleep time (TST) evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Stage 1 duration evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Stage 2 duration evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Stage 3 duration evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Stage 1 percentage evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Stage 2 percentage evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Stage 3 percentage evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary REM duration evaluated by polysomnography (PSG) In minutes During the 72 hours of the diagnostic' hospitalization
Primary REM percentage of TST evaluated by polysomnography (PSG) In percentage of TST During the 72 hours of the diagnostic' hospitalization
Primary Sleep efficiency evaluated by polysomnography (PSG) TST / SP in percentage During the 72 hours of the diagnostic' hospitalization
Primary Sleep latency evaluated by polysomnography (PSG) In minutes, first epoch of NREM or REM sleep During the 72 hours of the diagnostic' hospitalization
Primary REM latency evaluated by polysomnography (PSG) In minutes, first epoch of REM sleep from sleep onset During the 72 hours of the diagnostic' hospitalization
Primary Wake after sleep onset (WASO) duration evaluated by polysomnography (PSG) In minutes between sleep onset and sleep offset, During the 72 hours of the diagnostic' hospitalization
Primary Micro-arousal index evaluated by polysomnography (PSG) Number of event / hour During the 72 hours of the diagnostic' hospitalization
Primary Arousal index evaluated by polysomnography (PSG) During the 72 hours of the diagnostic' hospitalization
Primary Leg movements index evaluated by polysomnography (PSG) Number of event / hour During the 72 hours of the diagnostic' hospitalization
Primary Apnea-hypopnea index evaluated by polysomnography (PSG) Number of respiratory events / hour During the 72 hours of the diagnostic' hospitalization
Primary Mean saturation during sleep evaluated by polysomnography (PSG) In percentage During the 72 hours of the diagnostic' hospitalization
Primary Minimal saturation during sleep evaluated by polysomnography (PSG) In percentage During the 72 hours of the diagnostic' hospitalization
Primary Duration of SaO2<90% evaluated by polysomnography (PSG) In percentage of total sleep time During the 72 hours of the diagnostic' hospitalization
Primary Index of desaturation > 3% evaluated by polysomnography (PSG) Number of event / hour During the 72 hours of the diagnostic' hospitalization
Primary Maximal CO2 during non-REM sleep evaluated by polysomnography (PSG) In mmHg During the 72 hours of the diagnostic' hospitalization
Primary Maximal CO2 during REM sleep evaluated by polysomnography (PSG) In mmHg During the 72 hours of the diagnostic' hospitalization
Primary Sleep time with PCO2 > 50 mmHg / TST evaluated by polysomnography (PSG) In percentage During the 72 hours of the diagnostic' hospitalization
Primary Sleep latency evaluated during multiple sleep latency test (MSLT) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Stage 1 latency evaluated during multiple sleep latency test (MSLT) In minutes During the 72 hours of the diagnostic' hospitalization
Primary REM latency evaluated during multiple sleep latency test (MSLT) In minutes During the 72 hours of the diagnostic' hospitalization
Primary SOREM evaluated during multiple sleep latency test (MSLT) In minutes During the 72 hours of the diagnostic' hospitalization
Primary Power in frequency bands delta, alpha, gamma, theta evaluated during PSG During the 72 hours of the diagnostic' hospitalization
Primary Mean Bedtime evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Wake up time evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Time in bed evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Total Sleep time evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Waking time evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Sleep period evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Sleep efficiency evaluated by actimetry In percentage, during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean wake after sleep onset duration evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Sleep latency evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean fragmentation index evaluated by actimetry In percentage, during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Immobile time evaluated by actimetry In minutes, during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Moving time evaluated by actimetry In minutes, during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Number of immobile phases evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Mean Number of one minute immobility periods evaluated by actimetry during week-end days and week days During 15 days before the diagnostic' hospitalization
Primary Intellectual Quotient evaluated by the WISC by a neuropsychologist. During the 72 hours of the diagnostic' hospitalization
Primary Attention evaluated by the BLAST during neuropsychological evaluation During the 72 hours of the diagnostic' hospitalization
Primary Insomnia severity evaluated by Insomnia Severity Index (ISI) During the 72 hours of the diagnostic' hospitalization
Primary Depressive feelings evaluated by the Children Depression Inventory (CDI) During the 72 hours of the diagnostic' hospitalization
Primary Attention disorders symptoms evaluated by the Conners rating scale During the 72 hours of the diagnostic' hospitalization
Primary Fatigue evaluated by the Fatigue scale During the 72 hours of the diagnostic' hospitalization
Primary Estimated severity of the disease evaluated by the Severity scale During the 72 hours of the diagnostic' hospitalization
Primary Sleepiness evaluated by the Epworth sleepiness scale for children During the 72 hours of the diagnostic' hospitalization
Primary Sleepiness evaluated by the Karolinska scale During the 72 hours of the diagnostic' hospitalization
Primary Histamine rate in the cerebro-spinal fluid (CSF) , evaluated by lumbar punction In pg/mL During the 72 hours of the diagnostic' hospitalization
Primary Circadian typology evaluated by the Horne and Ostberg questionnaire During the 72 hours of the diagnostic' hospitalization
Primary Body fat evaluated by DEXA In percentage During the 72 hours of the diagnostic' hospitalization
Primary Lean mass evaluated by DEXA In percentage During the 72 hours of the diagnostic' hospitalization
Primary Leptin evaluated by blood test In ng/ml During the 72 hours of the diagnostic' hospitalization
Primary Total ghrelin evaluated by blood test During the 72 hours of the diagnostic' hospitalization
Primary Acylated ghrelin evaluated by blood test In pg/mL During the 72 hours of the diagnostic' hospitalization
Primary Non-acylated ghrelin ghrelin evaluated by blood test In pg/mL During the 72 hours of the diagnostic' hospitalization
Primary Fastin blood sugar evaluated by blood test In mmol/L During the 72 hours of the diagnostic' hospitalization
Primary Fasting insulin evaluated by blood test In mUI/L, During the 72 hours of the diagnostic' hospitalization
Primary Hba1C evaluated by blood test In percentage During the 72 hours of the diagnostic' hospitalization
Primary TSH evaluated by blood test In mUI/L During the 72 hours of the diagnostic' hospitalization
Primary T3 evaluated by blood test In pmol/L During the 72 hours of the diagnostic' hospitalization
Primary T4 evaluated by blood test In pmol/L During the 72 hours of the diagnostic' hospitalization
Primary Total cholesterol by blood test In mmol/L During the 72 hours of the diagnostic' hospitalization
Primary LDL by blood test In mmol/L During the 72 hours of the diagnostic' hospitalization
Primary HDL by blood test In mmol/L During the 72 hours of the diagnostic' hospitalization
Primary Triglycerides by blood test In mmol/L During the 72 hours of the diagnostic' hospitalization
Primary NFS by blood test During the 72 hours of the diagnostic' hospitalization
Primary Ionogram by blood test During the 72 hours of the diagnostic' hospitalization
Primary Epstein Barr Virus antibodies by serology Positivity During the 72 hours of the diagnostic' hospitalization
Primary Hepatitis B antibodies by serology Positivity During the 72 hours of the diagnostic' hospitalization
Primary Streptococcus antibodies by serology Positivity During the 72 hours of the diagnostic' hospitalization
Primary HLA evaluated by genotyping Presence of the known HLA factor of predisposition for narcolepsy, During the 72 hours of the diagnostic' hospitalization
Primary Urinary prolactin evaluated by urine test During the 72 hours of the diagnostic' hospitalization
Primary Urinary sulfatoxy-melatonin evaluated by urine test During the 72 hours of the diagnostic' hospitalization
Primary Urinary cortisol evaluated by urine test During the 72 hours of the diagnostic' hospitalization